NCT06525220 2026-02-23A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)Merus B.V.Phase 3 Recruiting500 enrolled
NCT05386550 2026-02-19Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)EMD SeronoPhase 3 Terminated166 enrolled 15 charts